Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 15-22

  Dupuis, L Lee ^a,b,c   Taylor, Tracey ^a   Saunders, E Fred ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone marrow transplant; Cyclosporine; Hematopoietic stem cell transplantation; HSCT; Pediatrics; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HURLER SYNDROME; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PEDIATRIC HOSPITAL; PROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; AGING; AREA UNDER CURVE; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER FUNCTION TESTS; MALE; PHARMACEUTICAL SOLUTIONS; SEX CHARACTERISTICS;

EID: 30544432743     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.15     Document Type: Article

References (32)

1. Martin P, Bleyzac N, Souillet G, et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003;32:777-84.
2. Ghalie R, Fitzsimmons WE, Weinstein A, Manson S, Kaizer H. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann Pharmacother 1994;28:379-83.
3. Przepiorka D, Shapiro S, Schwinghammer TL, et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low Cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 1991;7:461-5.
4. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998;4:157-63.
5. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum Cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988;319:65-70.
6. Hunter A, Bessell E, Russell N. Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant 1992;10:431-4.
7. Byrne J, Stainer C, Hyde H, et al. Low incidence of acute graft-versus-host disease and recurrent leukemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant 1998;22:541-5.
8. David-Neto E, Lemos F, Furusawa EA, et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol 2000;11:343-9.
9. Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003;32:881-7.
10. Schultz K, Nevill T, Balshaw R, et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant 2000;26:545-51.
11. Meier-Kriesche H, Swinford R, Kahan B, Brannan P, Portman RJ. Reduced variability of Neoral pharmacokinetic studies in pediatric renal transplantation. Pediatr Nephrol 2000;15:2-6.
12. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and Cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72.
13. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between Cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991;51(5):1014-18.
14. Giesbrecht E, Soldin S, Wong P. A reliable high-performance liquid Chromatographic micromethod for the measurement of Cyclosporine in whole blood. Ther Drug Monitoring 1989;11:332-6.
15. Hamwi A, Salomon A, Steinbrugger R, Fritzer-Szekeres M, Jager W, Szekeres T. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods. Am J Clin Pathol 2000;114:536-43.
16. Kabasakul SC, Clarke M, Kane H, Karsten J, Clark G. Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients. Pediatr Nephrol 1997;11:318-21.
17. Dotti G, Gaspari F, Caruso R, et al. Pharmacokinetic study of the new cyclosporin-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. Haematologica 2001;86:311-15.
18. Bokencamp A, Offner G, Hoyer P, Vester U, Wonigeit K, Brodehl J. Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. Pediatr Nephrol 1995;9:196-8.
19. Gusmano R, Verrina E, Piaggio G, Corbetta G, Basile G, Perfumo F. Pharmacokinetics of oral cyclosporine in children awaiting renal transplantation. Transplant Proc 1994;26:2781-3.
20. Cooney G, Lum B, Meligeni J, Dunn S. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Transplant Proc 1996;28:2270-2.
21. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 2002;73(suppl):S12-18.
22. Dirks M, Martin S, Hagen L, et al. Elevated serum trypsinogen among childhood allogeneic hematopoietic stem cell transplant recipients: an indicator of poor outcome [abstr]? J Pediatr Gastroenterol Nutr 2004;39(suppl 1):S365.
23. Taskinen M, Westerholm-Ormio M, Karikoski R, et al. Increased cell turnover, but no signs of increased T-cell infiltration or inflammatory cytokines in the duodenum of pediatric patients after allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34:221-8.
24. Johansson JE, Abrahamsson H, Ekman T. Gastric emptying after autologous haematopoietic stem-cell transplantation: a prospective trial. Bone Marrow Transplant 2003;32:815-19.
25. Schultz KR, Nevill TJ, Balshaw RF, et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant 2000;26:545-51.
26. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C2 monitoring: a review. Transplantation 2002;73(9suppl):S3-11.
27. Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant 2003;7:282-8.
28. Filler G, Feber J. The transplanted child: new immuno-suppressive agents and the need for pharmacokinetic monitoring. Paediatr Child Health 2002;7:525-32.
29. Kahan B, Ried M, Newburger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 1983;15(suppl 1):446-53.
30. Lemire J, Capparelli E, Benador N, Grimm P, MacDonald D, Reznik V. Neoral pharmacokinetics in Latino and Caucasian pediatric renal transplant recipients. Pediatr Nephrol 2001;16:311-14.
31. von Ahsen N, Helmhold M, Schutz E, Eisenhauer T, Armstrong VW, Oellerich M. Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. Ther Drug Monitoring 1997;19(2):140-5.
32. Lares-Asseff I, Zaltzman S, Guille M, et al. Pharmacokinetics of cyclosporine as a function of energy-protein deficiency in children with chronic renal failure. J Clin Pharmacol 1997;37:179-85.